Immunomodulatory therapy of cytomegalovirus pneumonia after liver transplantation

( views:75, downloads:0 )
Author:
WANG Gen-shu()
CHEN Gui-hua()
LU Min-qiang()
YANG Yang()
CAI Chang-jie()
YI Hui-min()
LI Hua()
XU Chi()
YI Shu-hong()
Journal Title:
CHINESE MEDICAL JOURNAL
Issue:
Volume 119, Issue 17, 2006
DOI:
Key Word:
liver transplantation;cytomegalovirus pneumonia;immunotherapy

Abstract: Background There has been increasing interest in the research into cytomegalovirus (CMV) pneumonia after liver transplantation (LT). This study was undertaken to investigate the immunomodulatory therapy of CMV pneumonia after LT.Methods Six patients with CMV pneumonia after LT from October 2003 to November 2005 were analyzed retrospectively. They were diagnosed according to clinical manifestations, chest X-ray findings and pathogenic changes and given comprehensive therapy including mainly immunomodulation therapy and anti-viral medication. At the early stage of CMV pneumonia, the dose of immunosuppressive agents was decreased or ceased, instead replaced by immunoenhancement therapy. During recovery period from CMV pneumonia, the dose of immunosuppressive agents was given again or enhanced, and immunoenhancement therapy was ceased.The liver function of the patients was monitored closely during the treatment.Results In this series, five patients were survived and one died. The liver function of the six patients remained normal during the treatment, and no episode of acute rejection took place.Conclusions Poor immunity is the pathogenic basis of CMV pneumonia after LT. At early stage of CMV pneumonia, the immunity of the patients should be enhanced, and during the recovery period from CMV pneumonia, immunosuppresants shoud be given again but immunoenhancement therapy ceased. Individualized immunomodulatory therapy is essential to the treatment of CMV pneumonia after LT.

  • [1]Nichols WG,Boeckh M.Recent advances in the therapy and prevention of CMV infections.J Clin Virol 2000;16:25-40.
  • [2]Ho M.Advances in understanding cytomegalovirus infection after transplantation.Transplant Proc 1994;26(5 Suppl 1):7-11.
  • [3]Sissons JGP,Carmichael AJ,McKinney N,Sinclair JH,Wills MR.Human cytomegalovirus and immunopathology.Springer Semin Immunopathol 2002; 24:169-185.
  • [4]Hei ZQ,Liu DZ,Luo CF,Li SR,Ma WH,Luo GJ.Perioperative changes of ventricular function and three indicators of myocardial injury during orthotopic liver transplantation.Chin Med J 2006; 119:939-943.
  • [5]Ma YK,Yan LN,Li B,Lu SC,Huang AH,Wen TF,et al.Diagnosis and treatment of bacterial pneumonia in liver transplantation recipients:report of 33 cases.Chin Med J 2005;118:1879-1885.
  • [6]de Maar EF,Verschuuren EAM,Harmsen MC,The TH,van Son WJ.Pulmonary involvement during cytomegalovirus infection in immunosuppressed patients.Transpl Infect Dis 2003; 5:112-120.
  • [7]Retiere C,Prod'homme V,Imbert-Marcille BM,Bonneville M,Vie H,Hallet M.Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1 proteins:a tool to study the fine specificity of the antiviral response.J Virol 2000; 74:3948-3952.
  • [8]Lunetta JM,Wiedeman JA.Latency-associated sense transcripts are expressed during in vitro human cytomegalovirus productive infection.Virology 2000; 278:467-476.
  • [9]Tomazin R,Boname J,Hegde NR,Lewlnsohn DM,Altschuler Y,Jones TR,et al.Cytomegalovirus US2destroys two components of the MHC class-Ⅱ pathway,preventing recognition by CD4+T cells.Nat Med 1999; 5:1039-1043.
  • [10]Odeberg J,Soderberg-Naucler C.Reduced expression of HLA class Ⅱ molecules and interleukin-10 and transforming growth factor beta1 -independent suppression of T-cell proliferation in human cytomegalovirus-infected macrophage cultures.J Virol 2001;75:5174-5181.
  • [11]Greijer AE,Verschuuren EA,Dekkers CA,Adriaanse HM,van der Bij W,The TH,et al.Expression dynamics of human cytomegalovirus immune evasion genes US3,US6,and US11 in the blood of lung transplant recipients.J Infect Dis 2001; 184:247-255.
  • [12]Halkic N,Ksontini R,Scholl B,Blanc C,Kovacsovics T,Meylan P,et al.Recurrent cytomegalovirus disease,visceral leishmaniosis,and Legionella pneumonia after liver transplantation:a case report.Can J Anaesth 2004;51:84-87.
  • [13]Mutimer D.CMV infection of transplant recipients.J Hepatol 1996; 25:259-269.
  • [14]Knollmann FD,Maurer J,Bechstein WO,Bock J,Maurer J,Radtke C,et al.Pulmonary disease in liver transplant recipients.Spectrum of CT features.Acta Radiol 2000;41:230-236.
  • [15]Falagas ME,Snydman DR,George MJ,Werner B,Ruthazer R,Griffith J,et al.Incidence and predictors of cytomegalovirus pneumonia in orthotopic liver transplant recipients.Boston Center for Liver Transplantation CMVIG Study Group.Transplantation 1996; 61:1716-1720.
  • [16]Wang GS,Li H,Chen GH,Lu MQ,Yang Y,Cai CJ,et al.Diagnosis and treatment of cytomegalovirus pneumonia after liver transplantation.Chin J Surg (Chin) 2005; 43:1512-1515.
  • [17]Seehofer D,Rayes N,Neumann UP,Meisel H,Oettle H,Nussler NC,et al.Changing impact of cytomegalovirus in liver transplantation-a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis.Transpl Int 2005; 18:941-948.
  • [18]Hsia J,Sztein MB,Naylor PH,Simon GL,Goldstein AL,Hayden FG,et al.Modulation of thymosin alpha 1 and thymosin beta 4 levels and peripheral blood mononuclear cell subsets during experimental rhinovirus colds.Lymphokine Res 1989;8:383-391.
  • [19]Sztein MB,Serrate SA,Goldstein AL.Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones.Proc Natl Acad Sci USA 1986; 83:6107-6111.
  • [20]Hadden JW,Saha A,Sosa M,Hadden EM.Immunotherapy with natural interleukins and/or thymosin alpha 1 potently augments T-lymphocyte responses of hyd rocortisone-treated aged mice.Int J Immunopharmacol 1995; 17:821-828.
  • [21]Roy R,Singh SM,Shanker A,Sodhi A.Mechanism of thymocyte apoptosis induced by serum of tumor-bearing host:the molecular events involved and their inhibition by thymosin alpha-1.Int J Immunopharmacol 2000;
  • [22]309-321.22.Giuliani C,Napolitano G,Mastino A,Di Vincenzo S,D'Agostini C,Grelli S,et al.Thymosin-alpha1 regulates MHC class Ⅰ expression in FRTL-5 cells at transcriptional level.Eur J Immunol 2000,30:778-786.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn